Fibromatosis-like metaplastic carcinoma is a special variant of spindle cell carcinoma, a type of metaplastic carcinomas. It has a favorable prognosis, unlike other metaplastic carcinomas, with a particular clinical behavior characterized by frequent local recurrence, the meager potential for axillary lymph nodes, and distant metastases. We presented the case of a 51-year-old female with a large mass on the left breast, which was successfully removed by surgical resection. The pathological diagnosis was fibromatosis-like metaplastic carcinoma with the help of morphology and immunohistochemistry adjustment.
Background: Granulosa cell tumor of the ovary is a rare disease and presents with two clinically and molecularly distinct subtypes: the juvenile and the adult type. GCT is considered as a malignant tumor with an indolent course and a tendency toward late recurrence. Purpose: To assess the clinical and paraclinical features, treatment findings, survival outcomes, and explored the prognostic factors in the granulosa cell tumor. Methods: The current study was conducted on 28 GCT patients who had surgical operations and adjuvant chemotherapy (stage IC-IV) by applying a retrospective cohort analysis. The clinical and paraclinical characteristics were recorded. Recurrent status was evaluated for analysis with clinical and paraclinical features and survival. All GCT patients’ survival were analyzed by using Kaplan-Meier and Log-Rank models. Results: 17.9% of patients experienced a relapse and two patients died due to disease. The mean time from initial diagnose to recurrence was 40.21 months. The 5-year OS and DFS of stage I-II were 100% and 80.8%, and of stage III were 50% and 25%, respectively. In survival analyses, using the log-rank test, age ≥50 years, irregular menstruation, stage I-II, and absence of residual lesion were all significant predictors for the improved DFS. Stage I-II and absence of residual lesion were associated significantly with better OS. Mean of age, FIGO stage, and residual lesion during surgery had significant differences to recurrent rate (p < <0.05). The multivariate model revealed that these factors didn’t remain as an independent prognostic variable. Conclusion: FIGO stage and residual lesion during surgery had significant differences in survival and recurrent rate.
A complex of G719X and S768I mutations is infrequently observed, constituting less than 0.3% of all EGFR‐positive non‐small cell lung cancer (NSCLC), and the response to first‐line TKIs is inconsistent in the literature. In this study, we report a patient with metastatic non‐small cell lung cancer carrying rare EGFR compound mutations of G719X and S768I who benefited from first‐line treatment with gefitinib in Vietnam. This patient had a prolonged response lasting over 44 months with first‐generation TKI. He continued to take gefitinib without experiencing serious adverse events. NSCLC with a rare complex of G719X and S768I mutation revealed a good response to gefitinib.
T263P mutation is one of the rare EGFR mutations located on chromosome 7p11.2, which is a change in amino acid residue at position 263 of the epidermal growth factor receptor protein, where L‐threonine has been replaced by L‐proline. This missense mutation in the extracellular EGFR domain is not well‐known in lung cancer. In this study, we first report a patient with advanced lung adenocarcinoma harbouring only a rare T263P EGFR mutation who benefited from first‐line afatinib therapy in Vietnam. The patient achieved a partial response with a time‐to‐treatment failure of 5 months. The patient subsequently received several chemotherapy regimens as the disease progressed, with overall survival of 17 months. Non‐small cell lung cancer with a rare T263P EGFR mutation responds to afatinib but has a poor prognosis. Further studies are needed to determine the efficacy of targeted therapies in this specific population.
Squamous cell carcinoma admixed with large-cell neuroendocrine carcinoma of the uterine cervix is an extremely rare malignancy with a poor prognosis. We report a 50-year-old woman with mixed squamous cell carcinoma and large-cell neuroendocrine carcinoma of the uterine cervix with an individual history of early-stage breast cancer. She was diagnosed preoperatively with cervical cancer stage FIGO 1B2. However, during surgery, a lesion was found in Douglas’s peritoneum. The histopathological result of surgical specimens was mixed squamous cell carcinoma and large-cell neuroendocrine carcinoma. Then, she received concurrent chemoradiotherapy. Currently, after 3 months of treatment, she has not developed recurrent lesions.
Hội chứng Meigs là một bệnh hiếm gặp được đặc trưng bởi tam chứng bao gồm: khối u buồng trứng lành tính, cổ chướng, và tràn dịch màng phổi. Ở phụ nữ mãn kinh xuất hiện tràn dịch màng phổi, cổ chướng, CA125 tăng cao, và khối phần phụ có tỷ lệ cao là tổn thương ác tính. Mặc dù vậy, chẩn đoán cuối cùng dựa trên mô bệnh học sau mổ. Hội chứng Meigs cần được phân biệt trong những trường hợp này. Trong bài viết này, chúng tôi trình bày trường hợp bệnh nhân 56 tuổi, nhập viện với một khối vùng chậu, tràn dịch màng phổi, cổ chướng, và nồng độ CA125 tăng cao. Bệnh nhân sau đó được phẫu thuật cắt bỏ phần phụ bên tổn thương, kết quả giải phẫu bệnh là u xơ buồng trứng.